EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE
Pre-LaunchNDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE by Cipla is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ].
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiretroviral agents that work synergistically to inhibit HIV-1 replication. The combination is administered orally once daily and represents a simplified treatment regimen for HIV management. This product addresses the need for convenient, multi-agent HIV therapy in a single tablet.
Pre-Launch
Pre-launch stage presents opportunity to build commercial infrastructure and establish market positioning in a competitive antiretroviral landscape; team expansion anticipated upon regulatory approval.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product offers entry-level to mid-career professionals the opportunity to shape market strategy and brand positioning in the high-volume HIV treatment segment. Success depends on regulatory approval, competitive differentiation, and effective market access execution; career growth potential varies significantly based on commercial performance post-launch.
Brand ManagerField Sales Representative
Worked on EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.